• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Mukesh G. Harisinghani, MD


  • Hedgire SS, Mino-Kenudson M, Elmi A, Thayer S, Fernandez-del Castillo C, Harisinghani MG.Enhanced primary tumor delineation in pancreatic adenocarcinoma using ultrasmall super paramagnetic iron oxide nanoparticle-ferumoxytol: an initial experience with histopathologic correlation.International Journal Of Nanomedicine. 2014;9:1891-6.
  • Hedgire SS, Eberhardt SC, Borczuk R, McDermott S, Harisinghani MG.Interpretation and reporting multiparametric prostate MRI: a primer for residents and novices.Abdom Imaging. 2014 Feb 25.
  • McDermott S, Thayer SP, Fernandez-Del Castillo C, Mino-Kenudson M, Weissleder R, Harisinghani MG.Accurate prediction of nodal status in preoperative patients with pancreatic ductal adenocarcinoma using next-gen nanoparticle.Transl Oncol. 2013 Dec 1;6(6):670-5.
  • Mitchell DG, Javitt MC, Glanc P, Bennett GL, Brown DL, Dubinsky T, Harisinghani MG, Harris RD, Horowitz NS, Pandharipande PV, Pannu HK, Podrasky AE, Royal HD, Shipp TD, Siegel CL, Simpson L, Wong-You-Cheong JJ, Zelop CM.ACR appropriateness criteria staging and follow-up of ovarian cancer.J Am Coll Radiol. 2013 Nov;10(11):822-7.
  • Olumi AF, Kaufman DS, Zietman A, Harisinghani MG, Wu CL.Case records of the Massachusetts General Hospital. Case 25-2013. A 71-year-old man with hematuria and a mass in the bladder.N Engl J Med. 2013 Aug 15;369(7):660-7.
  • Hedgire SS, Oei TN, McDermott S, Cao K, Patel M Z, Harisinghani MG.Multiparametric magnetic resonance imaging of prostate cancer.Indian J Radiol Imaging. 2012 Jul;22(3):160-9.
  • Preston MA, Harisinghani MG, Mucci L, Witiuk K, Breau RH.Diagnostic tests in urology: magnetic resonance imaging (MRI) for the staging of prostate cancer.BJU Int. 2013 Mar;111(3):514-7.
  • Paly JJ, Efstathiou JA, Hedgire SS, Chung PW, O'Malley M, Shah A, Bekelman JE, Harisinghani M, Shipley WU, Zietman AL, Beard C.Mapping patterns of nodal metastases in seminoma: rethinking radiotherapy fields.Radiother Oncol. 2013 Jan;106(1):64-8.
  • Hedgire SS, Elmi A, Nadkarni ND, Cao K, McDermott S, Harisinghani MG.Preoperative evaluation of perinephric fat invasion in patients with renal cell carcinoma: correlation with pathological findings.Clin Imaging.;37(1):91-6.
  • Hedgire SS, Pargaonkar VK, Elmi A, Harisinghani AM, Harisinghani MG.Pelvic nodal imaging.Radiol Clin North Am. 2012 Nov;50(6):1111-25.
  • Jhaveri KS, Harisinghani MG.Guest editors.Radiol Clin North Am. 2012 Nov;50(6):xi.
  • Hartman RI, Chang CY, Wo JY, Eisenberg JD, Hong TS, Harisinghani MG, Gazelle GS, Pandharipande PV.Optimizing Adjuvant Treatment Decisions for Stage T2 Rectal Cancer Based on Mesorectal Node Size: A Decision Analysis.Acad Radiol. 2012 Sep 1.
  • Kaufman DS, Zietman AL, Dahl DM, Harisinghani MG, Wu CL.Case records of the Massachusetts General Hospital. Case 5-2011. A 65-year-old man with hematuria after treatment for prostate cancer.N Engl J Med. 2011 Feb 17;364(7):667-75.
  • Saokar A, Gee MS, Islam T, Mueller PR, Harisinghani MG.Appearance of primary lymphoid malignancies on lymphotropic nanoparticle-enhanced magnetic resonance imaging using ferumoxtran-10.Clin Imaging.;34(6):448-52.
  • Islam T, Harisinghani MG.Prostate cancer imaging: what the next decade holds.Expert Rev Med Devices. 2010 Sep;7(5):577-9.
  • Saokar A, Islam T, Jantsch M, Saksena MA, Hahn PF, Harisinghani MG.Detection of lymph nodes in pelvic malignancies with Computed Tomography and Magnetic Resonance Imaging.Clin Imaging.;34(5):361-6.
  • Pandharipande PV, Gervais DA, Hartman RI, Harisinghani MG, Feldman AS, Mueller PR, Gazelle GS.Renal mass biopsy to guide treatment decisions for small incidental renal tumors: a cost-effectiveness analysis.Radiology. 2010 Sep;256(3):836-46.
  • Macdonald SM, Harisinghani MG, Katkar A, Napolitano B, Wolfgang J, Taghian AG.Nanoparticle-Enhanced MRI to Evaluate Radiation Delivery to the Regional Lymphatics for Patients With Breast Cancer.Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1098-104.
  • Uppot RN, Harisinghani MG, Gervais DA.Imaging-guided percutaneous renal biopsy: rationale and approach.AJR Am J Roentgenol. 2010 Jun;194(6):1443-9. Review.
  • Eisner BH, Kurtz MP, Harisinghani MG.Evolving role of magnetic resonance imaging in renal cancer imaging.J Endourol. 2010 May;24(5):707-11.
  • Iyer VR, Hahn PF, Blaszkowsky LS, Thayer SP, Halpern EF, Harisinghani MG.Added value of selected images embedded into radiology reports to referring clinicians.J Am Coll Radiol. 2010 Mar;7(3):205-10.
  • Ventura E, Islam T, Gee MS, Mahmood U, Braschi M, Harisinghani MG.Detection of nodal metastatic disease in patients with non-small cell lung cancer: comparison of positron emission tomography (PET), contrast-enhanced computed tomography (CT), and combined PET-CT.Clin Imaging.;34(1):20-8.
  • Kaufman DS, McDougal WS, Harisinghani MG, Wu CL.Case records of the Massachusetts General Hospital. Case 30-2009. A 77-year-old man with recurrent transitional-cell carcinoma of the ureter.N Engl J Med. 2009 Sep 24;361(13):1292-9.
  • Baier ND, Hahn PF, Gervais DA, Samir A, Halpern EF, Mueller PR, Harisinghani MG.Fine-needle aspiration biopsy of thyroid nodules: experience in a cohort of 944 patients.AJR Am J Roentgenol. 2009 Oct;193(4):1175-9.
  • Roedl JB,Blake MA,Holalkere NS,Mueller PR,Colen RR,Harisinghani MG.Lymph node staging in esophageal adenocarcinoma with PET-CT based on a visual analysis and based on metabolic parameters.Abdom Imaging.;34(5):610-7.
  • Pandharipande PV, Mora JT, Uppot RN, Goehler A, Braschi M, Halpern EF, Gazelle GS, Harisinghani MG.Lymphotropic nanoparticle-enhanced MRI for independent prediction of lymph node malignancy: a logistic regression model.AJR Am J Roentgenol. 2009 Sep;193(3):W230-7.
  • Ross RW, Zietman AL, Xie W, Coen JJ, Dahl DM, Shipley WU, Kaufman DS, Islam T, Guimaraes AR, Weissleder R, Harisinghani M.Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy.Clin Imaging.;33(4):301-5.
  • Islam T,Harisinghani MG.Overview of nanoparticle use in cancer imaging.Cancer Biomark. 2009;5(2):61-7. Review.
  • Harisinghani MG.Nanoparticle enhanced imaging.Cancer Biomark. 2009;5(2):59.
  • Gee MS,Harisinghani MG,Tabatabaei S.Molecular imaging in urologic surgery.Urol Clin North Am. 2009 May;36(2):125-32. Review.
  • Pandharipande PV,Harisinghani MG,Ozanne EM,Specht MC,Hur C,Lee JM,Gazelle GS.Staging MR lymphangiography of the axilla for early breast cancer: cost-effectiveness analysis.AJR Am J Roentgenol. 2008 Nov;191(5):1308-19.
  • Roedl JB,Harisinghani MG,Colen RR,Fischman AJ,Blake MA,Mathisen DJ,Mueller PR.Assessment of treatment response and recurrence in esophageal carcinoma based on tumor length and standardized uptake value on positron emission tomography-computed tomography.Ann Thorac Surg. 2008 Oct;86(4):1131-8.
  • Li CS,Harisinghani MG,Lin WC,Braschi M,Hahn PF,Mueller PR.Enhancement characteristics of ultrasmall superparamagnetic iron oxide particle within the prostate gland in patients with primary prostate cancer.J Comput Assist Tomogr. 2008 Jul-Aug;32(4):523-8.
  • Michaelson MD,Iliopoulos O,McDermott DF,McGovern FJ,Harisinghani MG,Oliva E.Case records of the Massachusetts General Hospital. Case 17-2008. A 63-year-old man with metastatic renal-cell carcinoma.N Engl J Med. 2008 May 29;358(22):2389-96.
  • Guimaraes AR, Tabatabei S, Dahl D, McDougal WS, Weissleder R, Harisinghani MG.Pilot study evaluating use of lymphotrophic nanoparticle-enhanced magnetic resonance imaging for assessing lymph nodes in renal cell cancer.Urology. 2008 Apr;71(4):708-12.
  • Feldman AS, McDougal WS, Harisinghani MG.The potential of nanoparticle-enhanced imaging.Urol Oncol. 2008 Jan-Feb;26(1):65-73. Review.
  • Harisinghani M, Ross RW, Guimaraes AR, Weissleder R.Utility of a new bolus-injectable nanoparticle for clinical cancer staging.Neoplasia. 2007 Dec;9(12):1160-5.
  • Singh AK, Gonzalez-Torrez P, Kaewlai R, Tabatabaei S, Harisinghani MG.Imaging of penile neoplasm.Semin Ultrasound CT MR. 2007 Aug;28(4):287-96. Review.
  • Ross R, Harisinghani M.Prostate cancer imaging--what the urologic oncologist needs to know.Radiol Clin North Am. 2006 Sep;44(5):711-22, viii. Review.
  • Ross R, Harisinghani M.New clinical imaging modalities in prostate cancer.Hematol Oncol Clin North Am. 2006 Aug;20(4):811-30. Review.
  • Shih HA, Harisinghani M, Zietman AL, Wolfgang JA, Saksena M, Weissleder R.Mapping of nodal disease in locally advanced prostate cancer: rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy.Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1262-9.
  • Kim JY, Harisinghani MG.MR imaging staging of pelvic lymph nodes.Magn Reson Imaging Clin N Am. 2004 Aug;12(3):581-6.
  • Harisinghani MG, Dixon WT, Saksena MA, Brachtel E, Blezek DJ, Dhawale PJ, Torabi M, Hahn PF.MR lymphangiography: imaging strategies to optimize the imaging of lymph nodes with ferumoxtran-10.Radiographics. 2004 May-Jun;24(3):867-78.
  • Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la Rosette J, Weissleder R.Noninvasive detection of clinically occult lymph-node metastases in prostate cancer.N Engl J Med. 2003 Jun 19;348(25):2491-9.